Malignancy Rates Through 4 Years Of Follow-Up In Guselkumab-Treated Moderate To Severe Psoriasis Patients From The Voyage 1 And 2 Trials And Comparisons To The General United States Population
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要